Freeport-McMoRan Inc vs Cassava Sciences Inc — how do they compare? Freeport-McMoRan Inc trades at $69.27 (market cap $96.42B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Freeport-McMoRan Inc is far larger — about 2019.3× Cassava Sciences Inc's market cap, and Freeport-McMoRan Inc pays a 0.87% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FCX | FLNA | |
|---|---|---|
Market Cap | $96.42B | $47.75M |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $4.64 |
52-Week Low | $35.34 | $0.87 |
Enterprise Value | $102.70B | -$34.93M |
Dividend Yield | 0.87% | — |
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.23, down 1.84% on the day, with a bullish technical signal supported by moving averages and strong support at $68. The company reported Q2 2026 EPS of $0.68, beating estimates, and maintains robust cash flow from operations of $5.61 billion in 2025. Recent news highlights growth from Grasberg ramp-up and copper market tailwinds.
Outlook is positive with a consensus price target of $73.85, reflecting 6.7% upside, driven by earnings beats and expansion projects. Risks include commodity price volatility and execution challenges at new mines. Analyst sentiment is strongly bullish with 61% buy ratings, but overbought RSI levels suggest near-term caution.
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
Trailing returns across standard periods
Latest headlines on both assets
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →